Istiratumab

Istiratumab is an experimental drug that is currently under investigation for its potential use in the treatment of cancer. It is a monoclonal antibody that targets the protein CD38, which is often overexpressed in certain types of cancer cells.

Mechanism of Action

Istiratumab works by binding to the CD38 protein on the surface of cancer cells. This binding triggers a series of events that lead to the death of the cancer cell. The exact mechanism by which this occurs is still under investigation, but it is thought to involve the activation of the immune system.

Clinical Trials

Several clinical trials have been conducted to assess the safety and efficacy of istiratumab in the treatment of various types of cancer. These trials have shown promising results, but further research is needed before the drug can be approved for use in the general population.

Side Effects

As with any drug, istiratumab has the potential to cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and fever. More serious side effects, such as infections and allergic reactions, have also been reported.

Future Research

Future research on istiratumab will focus on determining the optimal dosing regimen, identifying the types of cancer that respond best to the drug, and investigating potential combination therapies with other cancer drugs.

See Also

• Monoclonal antibodies
• Cancer treatment
• Clinical trial
• CD38 (protein)